bluebird bio (MEX:BLUE) ROCE % : -110.43% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is bluebird bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. bluebird bio's annualized ROCE % for the quarter that ended in Sep. 2024 was -110.43%.

bluebird bio ROCE % Historical Data

The historical data trend for bluebird bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio ROCE % Chart

bluebird bio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-30.54

-37.24

-57.35

-51.06

-43.79

bluebird bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-68.06	-69.42	-67.79	-109.75	-110.43

bluebird bio ROCE % Calculation

bluebird bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3321.623	/	( ( (11109.094 - 3052.664)	+	(10509.792 - 3396.768) )	/ 2 )
	=	-3321.623	/	( (8056.43	+	7113.024)	/ 2 )
	=	-3321.623	/	7584.727
	=	-43.79 %

bluebird bio's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-4338.796	/	( ( (9987.992 - 5458.108)	+	(9157.092 - 5828.959) )	/ 2 )
	=	-4338.796	/	( ( 4529.884	+	3328.133 )	/ 2 )
	=	-4338.796	/	3929.0085
	=	-110.43 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

bluebird bio (MEX:BLUE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

bluebird bio ROCE % Related Terms

Thank you for viewing the detailed overview of bluebird bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

bluebird bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (MEX:BLUE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BLUE:USA 0HOH:UK

Address

455 Grand Union Boulevard, Somerville, MA, USA, 02145

Website

https://www.bluebirdbio.com

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.